nach oben

Archives of Virology

Erschienen in:

08.06.2020 | COVID-19 | Review Zur Zeit gratis

The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review

verfasst von: William Gustavo Lima, Júlio César Moreira Brito, Joerg Overhage, Waleska Stephanie da Cruz Nizer

Erschienen in: Archives of Virology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

The novel human coronavirus (SARS-CoV-2), the causative agent of COVID-19, has quickly become a threat to the public health and economy worldwide. Despite the severity of some cases, there are no current pathogen-specific antivirals available to treat the disease. Therefore, many studies have focused on the evaluation of the anti-SARS-CoV-2 activity of clinically available drugs. Here, we conducted a systematic review to describe the drug repositioning strategy against SARS-CoV-2 and to discuss the clinical impact of this approach in the current pandemic context. The systematic review was performed on March 23, 2020, using PubMed/MEDLINE, Scopus, Cochrane Library, and Biblioteca Virtual de Saúde (BVS). The data were summarized in tables and critically analyzed. After the database search, 12 relevant studies were identified as eligible for the review. Among the drugs reported in these studies, 57 showed some evidence of antiviral activity. Antivirals, especially antiretrovirals, are the main class of therapeutic agents evaluated against COVID-19. Moreover, studies have reported the anti-SARS-CoV-2 activity of antitumor (16%; 9/57), antimalarial (7%, 4/57), and antibacterial (5%; 3/57) agents. Additionally, seven pharmacological agents (chloroquine, tetrandrine, umifenovir (arbidol), carrimycin, damageprevir, lopinavir/ritonavir) are in phase IV of clinical trials. Due to the evidence of the anti-SARS-CoV-2 activity of various clinically available agents, drug repositioning stands out as a promising strategy for a short-term response in the fight against the novel coronavirus.

Nur mit Berechtigung zugänglich

Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. https://doi.org/10.1056/NEJMoa2001017 CrossRefPubMedPubMedCentral

De Wit E, Van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. https://doi.org/10.1038/nrmicro.2016.81 CrossRefPubMedPubMedCentral

de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ (2018) Host factors in coronavirus replication. In: Ahmed R, Akira S, Aktories K, Casadevall A, Compans RW, Galan JE, Garcia-Sastre A, Malissen B, Rappuoli R (eds) Current topics in microbiology and immunology, 3rd edn. Springer Verlag, Switzerland, pp 1–42

Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 CrossRefPubMedPubMedCentral

Paules CI, Marston HD, Fauci AS (2020) Coronavirus Infections-More Than Just the Common Cold. JAMA - J Am Med Assoc 323:707–708. https://doi.org/10.1001/jama.2020.0757 CrossRef

Worldometer (2020) Coronavirus Cases. Worldometer. https://www.worldometers.info/coronavirus/. Accessed 15Apr 2020

Meraw S (2020) The global macroeconomic impacts of COVID-19: Seven scenarios. Brookings. https://www.brookings.edu/research/the-global-macroeconomic-impacts-of-covid-19-seven-scenarios/. Accessed 26 Mar 2020

Chong CR, Sullivan DJ (2007) New uses for old drugs. Nature 448:645–646. https://doi.org/10.1038/448645a CrossRefPubMed

Padhy BM, Gupta YK (2011) Drug repositioning: Re-investigating existing drugs for new therapeutic indications. J Postgrad Med 57:153–160. https://doi.org/10.4103/0022-3859.81870 CrossRefPubMed

10.

Lima WG, Alves-Nascimento LA, Andrade JT et al (2019) Are the Statins promising antifungal agents against invasive candidiasis? Biomed Pharmacother 111:270–281. https://doi.org/10.1016/j.biopha.2018.12.076 CrossRefPubMed

11.

Higgins JPT, Green S (editors) (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. https://training.cochrane.org/handbook. Accessed 15 Apr 2020

12.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. https://doi.org/10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentral

13.

Landis Richard, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174. https://doi.org/10.2307/2529310 CrossRefPubMed

14.

Wang Z, Chen X, Lu Y et al (2020) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 14:64–68. https://doi.org/10.5582/bst.2020.01030 CrossRefPubMed

15.

Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2001282 CrossRefPubMedPubMedCentral

16.

Mo P, Xing Y, Xiao Y et al (2020) Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 5:4. https://doi.org/10.1093/cid/ciaa270 CrossRef

17.

Holshue ML, DeBolt C, Lindquist S et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936. https://doi.org/10.1056/NEJMoa2001191 CrossRefPubMedPubMedCentral

18.

Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269–271CrossRefPubMedPubMedCentral

19.

Liu J, Cao R, Xu M et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https://doi.org/10.1038/s41421-020-0156-0 CrossRefPubMedPubMedCentral

20.

Chen YW, Yiu C-PB, Wong K-Y (2020) Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research 9:129. https://doi.org/10.12688/f1000research.22457.1 CrossRefPubMedPubMedCentral

21.

Xu Z, Peng C, Shi Y, et al (2020) Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. https://doi.org/10.1101/2020.01.27.921627

22.

Li Y, Zhang J, Wang N et al (2020) Therapeutic drugs targeting 2019-ncov main protease by high-throughput screening. bioRxiv. https://doi.org/10.1101/2020.01.28.922922 CrossRefPubMedPubMedCentral

23.

Liu X, Wang X-J (2020) Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv 5:12. https://doi.org/10.1101/2020.01.29.924100 CrossRef

24.

Beck BR, Shin B, Choi Y et al (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv. https://doi.org/10.1101/2020.01.31.929547 CrossRefPubMedPubMedCentral

25.

Shi H, Han X, Zheng C (2020) Evolution of CT manifestations in a patient eecovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, Chinaa. Radiology 295:20. https://doi.org/10.1148/radiol.2020200269 CrossRefPubMed

26.

Tingting S (2020) Li Lanjuan’s team: Abidol and darunavir can effectively inhibit coronavirus. China News Network. http://www.sd.chinanews.com/2/2020/0205/70145.html. Accessed 26 Mar 2020 (in Chinese)

27.

Rodríguez-Morales AJ, MacGregor K, Kanagarajah S et al (2020) Going global—Travel and the 2019 novel coronavirus. Travel Med Infect Dis. 33:101578. https://doi.org/10.1016/j.tmaid.2020.101578 CrossRefPubMedPubMedCentral

28.

Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63:769–802. https://doi.org/10.2165/00003495-200363080-00004 CrossRefPubMed

29.

De Wilde AH, Jochmans D, Posthuma CC et al (2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:4875–4884. https://doi.org/10.1128/AAC.03011-14 CrossRefPubMedPubMedCentral

30.

Chan JF-W, Yao Y, Yeung M-L et al (2015) Treatment With Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904–1913. https://doi.org/10.1093/infdis/jiv392 CrossRefPubMed

31.

Boriskin Y, Leneva I, Pecheur E-I, Polyak S (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15:997–1005. https://doi.org/10.2174/092986708784049658 CrossRefPubMed

32.

Blaising J, Polyak SJ, Pécheur EI (2014) Arbidol as a broad-spectrum antiviral: An update. Antivir Res. 107:84–94. https://doi.org/10.1016/j.antiviral.2014.04.006 CrossRefPubMed

33.

Khamitov RA, Loginova SI, Shchukina VN et al (2008) Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 53:9–13 (Article in Russian) PubMed

34.

Hoenen T, Groseth A, Feldmann H (2019) Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol 17:593–606. https://doi.org/10.1038/s41579-019-0233-2 CrossRefPubMed

35.

Agostini ML, Andres EL, Sims AC et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9:e00221-18. https://doi.org/10.1128/mBio.00221-18 CrossRefPubMedPubMedCentral

36.

Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166. https://doi.org/10.1038/s41584-020-0372-x CrossRefPubMed

37.

Keyaerts E, Vijgen L, Maes P et al (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264–268. https://doi.org/10.1016/j.bbrc.2004.08.085 CrossRefPubMedPubMedCentral

38.

Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69 CrossRefPubMedPubMedCentral

Titel: The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review
verfasst von: William Gustavo Lima
Júlio César Moreira Brito
Joerg Overhage
Waleska Stephanie da Cruz Nizer
Publikationsdatum: 08.06.2020
Verlag: Springer Vienna
Schlagwort: COVID-19
Erschienen in: Archives of Virology / Ausgabe 8/2020
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-020-04693-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Complete genome sequence analysis of a genetic variant of grapevine virus L from the grapevine cultivar Blanc du Bois

Correction to: Characterization and genome sequencing of three Aeromonas hydrophila-specific phages, CF8, PS1, and PS2

Comparative analysis of a Thai congenital-Zika-syndrome-associated virus with a Thai Zika-fever-associated virus

Investigation of Crimean-Congo hemorrhagic fever virus in ruminant species slaughtered in several endemic provinces in Turkey

Codiaeum variegatum in Pakistan harbours pedilanthus leaf curl virus and papaya leaf curl virus as well as a newly identified betasatellite